⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15707248 | 0.76 | — | — | |
| SCHEMBL822679 | 0.72 | — | — | |
| SCHEMBL21957490 | 0.72 | HSD17B10 (0.36) | — | |
| SCHEMBL21030319 | 0.70 | — | — | |
| SCHEMBL12410805 | 0.69 | LMNA (0.44) | — | |
| SCHEMBL859443 | 0.69 | — | — | |
| SCHEMBL21719839 | 0.69 | — | — | |
| SCHEMBL1393546 | 0.69 | HSD17B10 (0.37) | — | |
| SCHEMBL17034548 | 0.69 | — | — | |
| SCHEMBL22250453 | 0.68 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 193 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12595249-B2 | Aryl ether-substituted heterocyclic compounds as glpir agonists | MINDRANK AI LTD. (CN) | 2026-04-07 | — | — | US | disclosed |
| US-12497384-B2 | Aryl ether-substituted heterocyclic compounds as GLP1R agonists | MINDRANK AI LTD. (CN) | 2025-12-16 | — | — | US | disclosed |
| US-20250353853-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-11-20 | — | — | US | disclosed |
| US-20250304553-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-10-02 | — | — | US | disclosed |
| US-20250282757-A1 | ARYL ETHER-SUBSTITUTED HETEROCYCLIC COMPOUNDS AS GLP1R AGONISTS | MINDRANK AI LTD. (CN) | 2025-09-11 | — | — | US | disclosed |
| US-20250195480-A1 | MACROCYCLIC AZOLOPYRIDINE DERIVATIVES AS EED AND PRC2 MODULATORS | Fulcrum Therapeutics, Inc. | 2025-06-19 | — | — | US | disclosed |
| EP-4532476-A1 | FLAVIVIRUS INHIBITORS | IRBM S.P.A. (IT) | 2025-04-09 | — | — | EP | disclosed |
| CN-117242067-B | Novel aryl ether substituted heterocycles as GLP1R agonists | 杭州德睿智药科技有限公司 | 2025-03-25 | — | — | CN | disclosed |
| CN-119630645-A | Flavivirus inhibitors | IRBM股份公司 | 2025-03-14 | — | — | CN | disclosed |
| US-12109198-B2 | Macrocyclic azolopyridine derivatives as EED and PRC2 modulators | Fulcrum Therapeutics, Inc. (US) | 2024-10-08 | — | — | US | disclosed |
| EP-2076512-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-07-08 | — | — | EP | disclosed |
| US-20090137815-A1 | Process for Making Cytokine Inhibiting Compounds Containing 4- and 5-Imidazolyl Rings and the Intermediates Thereof | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-05-28 | — | — | US | disclosed |
| EP-2035436-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB Pharma S.A. (BE) | 2009-03-18 | — | — | EP | disclosed |
| EP-2010522-A1 | PROCESS FOR MAKING CYTOKINE INHIBITING COMPOUNDS CONTAINING 4- AND 5- IMIDAZOLYL RINGS AND THE INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-01-07 | — | — | EP | disclosed |
| WO-2009000819-A1 | 5-PHENYL-1,3,4-OXADIAZOL-2-YL-ACETYL-4-PIPERIDINYL DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| WO-2009000819-A1 | 5-PHENYL-1,3,4-OXADIAZOL-2-YL-ACETYL-4-PIPERIDINYL DERIVATIVES AS CGRP RECEPTOR ANTAGONISTS | GLAXO GROUP LIMITED (GB) | 2008-12-31 | — | — | WO | disclosed |
| WO-2008079836-A2 | MACROCYCLIC FACTOR VIIA INHIBITORS USEFUL AS ANTICOAGULANTS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2008-07-03 | — | — | WO | disclosed |
| WO-2008044022-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-04-17 | — | — | WO | disclosed |
| WO-2008001076-A1 | FUSED THIAZOLE DERIVATIVES AS KINASE INHIBITORS | UCB PHARMA S.A. (BE) | 2008-01-03 | — | — | WO | disclosed |
| WO-2007121390-A1 | PROCESS FOR MAKING CYTOKINE INHIBITING COMPOUNDS CONTAINING 4- AND 5- IMIDAZOLYL RINGS AND THE INTERMEDIATES THEREOF | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-10-25 | — | — | WO | disclosed |